Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR26320078

—

4c53099f-f945-5b80-bb5f-2e2fb7d42eef

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.470
  • G2M_CHECKPOINT+0.390
  • INTERFERON_ALPHA_RESPONSE+0.380
  • ESTROGEN_RESPONSE_LATE+0.300
  • INTERFERON_GAMMA_RESPONSE+0.270
  • MITOTIC_SPINDLE+0.270
  • ALLOGRAFT_REJECTION+0.240
  • MYOGENESIS+0.210
  • ESTROGEN_RESPONSE_EARLY+0.180
  • APICAL_SURFACE+0.170

Top 10 suppressed

  • PROTEIN_SECRETION-0.330
  • TGF_BETA_SIGNALING-0.300
  • ADIPOGENESIS-0.280
  • KRAS_SIGNALING_UP-0.260
  • OXIDATIVE_PHOSPHORYLATION-0.250
  • WNT_BETA_CATENIN_SIGNALING-0.250
  • ANDROGEN_RESPONSE-0.240
  • UNFOLDED_PROTEIN_RESPONSE-0.190
  • ANGIOGENESIS-0.170
  • NOTCH_SIGNALING-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1X55c46455.46e3.40c2.ba37.333e25431e91
lung-landscapes@6
—cohortA40.717
2TCGA-85-8584-01A-11R-2403-07
lung-landscapes@6
—cohortA40.641
3MNG91
mng-umap@100
——0.640
4MNG645
mng-umap@100
——0.638
5SRR1516076
bladder-landscape@3
——0.636
6SRR10900562
melanoma-umap@29
——0.635
7SRR12202495
bladder-landscape@3
——0.616
8C3L-02969
lung-landscapes@6
—cohortSQ20.615
9DRR168510
bladder-landscape@3
——0.615
10TCGA-62-8394-01A-11R-2326-07
lung-landscapes@6
—cohortA10.614

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 31 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.470Inavolisib— uncovered
G2M_CHECKPOINT0.390Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.380Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.300Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.270Idelalisib— uncovered
MITOTIC_SPINDLE0.270Inavolisib— uncovered
ALLOGRAFT_REJECTION0.240Idelalisib— uncovered
MYOGENESIS0.210Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.180Inavolisib— uncovered
APICAL_SURFACE0.170Temsirolimus— uncovered
KRAS_SIGNALING_DN0.170Remibrutinib— uncovered
APICAL_JUNCTION0.150Inavolisib— uncovered
APOPTOSIS0.150Idelalisib— uncovered
COAGULATION0.150Binimetinib— uncovered
GLYCOLYSIS0.150Inavolisib— uncovered
DNA_REPAIR0.140Idelalisib— uncovered
HYPOXIA0.140Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.100Remibrutinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.090Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.080Inavolisib— uncovered